Effects of atypical antipsychotic drug treatment on amphetamine induced striatal dopamine release in patients with psychotic disorders

Neuropsychopharmacology

Volumn 20, Issue 4, 1999, Pages 340-345

  Breier, Alan ^a   Su, Tung Ping ^a   Malhotra, Anil K ^a   Elman, Igor ^a   Adler, Caleb M ^a   Weisenfeld, Neil I ^a   Pickar, David ^a  

^a Experimental Therapeutics Branch   (United States)

Author keywords

Clozapine; Positron emission tomography; Raclopride; Risperidone; Schizophrenia

Indexed keywords

AMPHETAMINE; CARBON 11; CLOZAPINE; NEUROLEPTIC AGENT; RACLOPRIDE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORPUS STRIATUM; DOPAMINE RELEASE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PSYCHOSIS;

ADULT; AMPHETAMINE; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEOSTRIATUM; PSYCHOTIC DISORDERS; RACLOPRIDE; RISPERIDONE; SALICYLAMIDES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033028756     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00126-2     Document Type: Article

References (43)

1. Breier A., Su T.-P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations. Evidence from a novel positron emission tomography method Proc Natl Acad Sci USA. 94:1997;2569-2574.
2. Breier A., Adler C.M., Weisenfeld N., Su T.-P., Elman I., Picken L., Malhotra A.K., Pickar D. Effects of NMDA antagonism on striatal dopamine release in healthy subjects. application of a novel PET approach Synapse. 29:1998;142-147.
3. Bunney B.S., Aghajanian G.K. Electrophysiological effects of amphetamine on dopaminergic neurons. Snyder S., Usdin E. Frontiers in Catecholamine Research. 1973;957-962 Pergamon Press, New York.
4. Bunney B.S., Aghajanian G.K. The effect of antipsychotic drugs on the firing of dopaminergic neurons. A reappraisal Sedvall G., Uvnas B., Zotterman Y. Antipsychotic Drugs. Pharmacodynamics and Pharmacokinetics:1976;305-318 Pergamon Press, New York.
5. Bunney B.S. Clozapine. a hypothesized mechanism for its unique clinical profile Br J Psychiatry. 160(suppl 17):1992;17-21.
6. Carson R., Channing M.A., Blasberg R.G., Dunn R.B., Cohen R.M., Rice K.C., Herscovitch P. An approximation formula for the variance of PET region-of-interest values. Journal of Cerebral Blood Flow and Metabolism. 13:1993;24-42.
7. 11C]-raclopride binding with continuous infusion. Journal of Cerebral Blood Flow and Metabolism. 17:1997;437-447.
8. Chiodo L.A., Bunney B.S. Typical and atypical neuroleptics. Differential effects of chronic administration of the activity of A9 and A10 midbrain dopaminergic neurons J Neurosci. 3:1983;1607-1619.
9. Chiodo L.A., Bunney B.S. Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J Neurosci. 5:1985;2539-2544.
10. Chiodo L.A. Dopamine-containing neurons in the mammalian central nervous system. Electrophysiology and pharmacology Neurosci Biobehav Rev. 12:1988;49-91.
11. 2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients. Biol Psychiatry. 29:1991;629-634.
12. Deutch A.Y., Moghaddam B., Innis R.B., Krystal J.H., Aghajanian G.K., Bunney B.S., Charney D.S. Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia Schizophrenia Research. 4:1991;121-156.
13. Deutch A.Y., Lee M.C., Iadarola M.J. Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression. the nucleus accumbens shell as a locus of antipsychotic action Molec Cell Neurosci. 3:1992;332-341.
14. 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse. 13:1993;350-356.
15. Endres C.J., Kolachana B.S., Saunders R.C., Su T.-P., Weinberger D., Breier A., Eckelman W.C., Carson R.E. Kinetic modeling of [11C]-Raclopride. Combined PET-microdialysis studies Journal of Cerebral Blood Flow and Metabolism. in press:1997.
16. 2 dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry. 45:1988;71.
17. 2 dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psycho pharmacology. 99:1989;S28-S31.
18. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and cloza pine. Relation to extrapyramidal side effects Arch Gen Psychiatry. 49:1992;538-544.
19. Fischer J., Cho A. Chemical release of dopamine from striatal homogenates. Evidence for an exchange diffusion model Journal of Pharmacology and Experimental Therapeutics. 192:1979;642-653.
20. 2 antagonist, in electrophysiological test predictive of antipsychotic activity. J Pharmacol Exp Ther. 249(3):1986;673-679.
21. 2 dopamine receptors J Nuclear Medicine. 36(7):1995;1275-1281.
22. 2 receptor in nonhuman primates. Synapse. 10:1992;177-184.
23. 2 antagonistic properties. J Pharmacol Exp Ther. 244:1988;685-693.
24. Kane J.M., Honigfeld G., Singer J., Meltzer H., the Clozaril Collaborative Study Group Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiat. 45:1988;789-796.
25. 2 dopamine receptor binding differences of clozapine and haloperidol. J Neural Transm. 86:1991;163-173.
26. 2 receptor occupancy in vivo and response to the new antipsychotic risperidone (letter). Br J Psychiatry. 163:1993;833-834.
27. 2 receptors in the human brain. Eur J Pharmacol. 223:1992;105-107.
28. Laruelle M., Abi-Dargham A., van Dyck H., Gill R., D'Souza D., Erdos J., McCance-Katz E., Rosenblatt W., Fingado C., Zoghbi S., Baldwin R., Seibyl J.P., Krystal J., Charney D., Innis R. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA. 93:1996;9235-9240.
29. Leysen J.E., Gommeren W., Eens A., De Chaffoy de Courcelles D., Stoof J.C., Janssen P.A.J. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther. 247:1988;661-670.
30. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 151:1994;825-835.
31. Meltzer H.Y. The mechanism of action of novel anti psychotic drugs. Schizophrenia Bull. 17:1991;263-287.
32. Nguyen T.Y., Kosofsky B.E., Birnbaum R., Cohen B.M., Hyman S.E. Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc Natl Acad Sci USA. 89:1992;4270-4274.
33. 2 dopamine receptor occupancy in relation to antipsychotic drug effects. A double-blind PET study of schizophrenic patients Biol Psychiatry. 33:1993;227-235.
34. 2 dopamine receptor occupancy induced by Olanzapine in healthy subjects. Neuropsychopharmacology. 16(1):1997;1-7.
35. 2 dopamine receptor occupancy in Clozapine-treated patients. Am J Psychiatry. 153(12):1996;1571-1578.
36. 123IBZM SPET (single photon emission tomography) study Psychol Med. 23:1993;791-797.
37. Robertson G.S., Fibiger H.C. Neuroleptics increase c-fos expression in the forebrain. Contrasting effects of haloperidol and clozapine Neuroscience. 46:1992;315-328.
38. Skarsfeldt T. Electrophysiological profile of the new atypical neuroleptic, Sertindole, on midbrain dopamine neurones in rats. Acute and repeated treatment Synapse. 10:1992;25-33.
39. Stockton M.E., Rasmussen K. Electrophysiological effects of Olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharm. 14(2):1996;97-104. a.
40. Stockton M.E., Rasmussen K. Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells. Psychopharmacology. 124:1996;50-56. b.
41. White F.J., Wang R.Y. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science. 221:1983;1054-1057.
42. Wiesel F.-A., Farde L., Nordstrom A.-L., Sedvall G. Central D1 and D2 receptor occupancy during antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry. 14:1990;759-767.
43. Wolkin A., Brodie J.D., Barouche F., Rotrosen J., Wolf A.P., Smith M., Fowler J.S., Cooper T.B. Dopamine receptor occupancy and plasma haloperidol levels. Arch Gen Psychiatry. 46:1989;482-484.